The mission details of the funder are not explicitly provided in the given description.
The grant program aims to advance the development and validation of biomarkers for Alzheimer's disease and related dementias, addressing a clear clinical need. It prioritizes biomarkers that have a defined context of use, demonstrate an advantage over existing ones, and show potential for commercialization or clinical application. The focus is on: developing novel PET ligands for clinical trials, supporting innovative CSF biomarkers, validating MRI approaches in larger cohorts, and creating new measures of functional activity such as EEG. High priority areas include novel biomarkers of neuroinflammation, synaptic integrity, autophagy, and TDP-43, among others. The grant offers up to $600,000 depending on the stage and scope of research, for one year, with the possibility of additional funding, covering only direct costs.
est consectetur velit enim anim aliquip